ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

Herpes zoster, inactivated vaccine (2027)

Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · Transparency notice on Find a Tender

Tender information last checkedLast checked 3 Oct 2026, 21:37.

Opportunity overview

The provision of a vaccine to protect against herpes zoster, also known as shingles, to be used in the national immunisation programme. This notice provides an indication to the market of UKHSA’s intention to enter into negotiations with GlaxoSmithKline (UK) Limited, with the objective of awarding a contract for the supply of the herpes zoster, inactivated (shingles) vaccine, in accordance with JCVI advice.

Awarded to

Amounts belong to published awards or contracts. Where several suppliers share one value, it is labelled as shared and is not a supplier-specific allocation.

GlaxoSmithKline UK Limited

Matched by exact name
Published award value
Value not stated
Awarded
Not supplied
Award ID
1
Status
pending
Identifier
GB-PPON PNVC-2547-YXMP
Location
London, UKI31, WC1A 1DG, United Kingdom

Classification

No classification was supplied.

Lots

  • Lot 1Value not stated

Documents and notices

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
CM/PHV/27/C384964
Status
complete
Procurement Method
direct
Procurement Method Details
Direct award
Why this procedure was chosen
The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023— (a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and (b)there are no reasonable alternatives to those goods, services or works.
Published risks
The below known unknown risks has been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise. Risk 1: The COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year. How the risk may impact on the performance of the contract: A health emergency or pandemic may materially affect the uptake of the herpes zoster, inactivated vaccine. Continued delivery of the vaccine within the original term of the contract could jeopardise stock management and effective use of vaccines before expiry. Why is it not possible to address the potential impact of such risks? UKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake.

Legal basis

Id
2023/54
Scheme
UKPGA

Procedure reasons

Entry 1
Id
singleSuppliersIntellectualPropertyExclusiveRights

Lots and requirements

Entry 1
Id
1
Status
complete

Published documents

Entry 1
Id
conflictOfInterest
Document Type
conflictOfInterest
Description
Not published

Buyer, suppliers and contacts

Organisation 1
Name
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency
Id
GB-PPON-PBMQ-7576-DVGW

Identifier

Scheme
GB-PPON
Id
PBMQ-7576-DVGW

Address

Street Address
10 South Colonnade
Locality
London
Postal Code
E14 4PU
Country
GB
Country Name
United Kingdom
Region
UKI42

Contact

Roles

buyer

Details

Classifications

Entry 1
Scheme
UK_CA_TYPE
Id
publicAuthorityCentralGovernment
Description
Public authority - central government
Organisation 2
Name
GlaxoSmithKline UK Limited
Id
GB-PPON-PNVC-2547-YXMP

Identifier

Scheme
GB-PPON
Id
PNVC-2547-YXMP

Address

Street Address
79 New Oxford Street
Locality
London
Postal Code
WC1A 1DG
Country
GB
Country Name
United Kingdom
Region
UKI31

Contact

Roles

supplier

Details

Scale
large
Vcse
No

Award information

Award 1
Id
1
Title
Herpes zoster, inactivated vaccine (2027)
Status
pending
Main Procurement Category
goods
Above Threshold
Yes
Has Renewal
Yes

Items

Item 1
Id
1
Related Lot
1

Additional Classifications

Entry 1
Scheme
CPV
Id
33651600
Description
Vaccines

Delivery locations

Entry 1
Region
UK
Country
GB
Country Name
United Kingdom

Value

Including VAT
0
Amount
0
Currency
GBP

Suppliers

Supplier 1
Id
GB-PPON-PNVC-2547-YXMP
Name
GlaxoSmithKline UK Limited

Contract period

Starts
1 Apr 2027, 00:00
Ends
31 Mar 2029, 23:59
Max Extent Date
31 Mar 2031, 23:59

Renewal

Description
The Authority has the option to extend for a period or periods of up to an additional 24 months, subject to negotiation.

Related lots

1

Documents

Entry 1
Id
022642-2026
Document Type
awardNotice
Notice Type
UK5
Description
Transparency notice on Find a Tender
Published
13 Mar 2026, 08:02
Format
text/html

Milestones

Entry 1
Id
1
Type
futureSignatureDate
Due
6 Nov 2026, 23:59
Status
scheduled

Recorded locations

  • Buyer location · London · UKI42 · E14 4PU · United Kingdom

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. 022642-2026Transparency notice on Find a Tender ·